Shawn Singh - 29 Dec 2023 Form 4 Insider Report for Vistagen Therapeutics, Inc. (VTGN)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Cynthia Anderson, Attorney-in-Fact
Issuer symbol
VTGN
Transactions as of
29 Dec 2023
Net transactions value
+$287
Form type
4
Filing time
03 Jan 2024, 17:17:08 UTC
Previous filing
05 Jul 2023
Next filing
26 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VTGN Common Stock Award $287 +167 +3.1% $1.72 5,633 29 Dec 2023 Direct F1
holding VTGN Common Stock 20,875 29 Dec 2023 By The 1997 Singh Family Trust U/R/D 05/29/97
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares purchased pursuant to the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan.